In a significant development within the healthcare sector, U.S. President Donald Trump has announced a deal with Eli Lilly and Novo Nordisk to lower the prices of GLP-1 weight-loss medications. This announcement took place during a notable event in the Oval Office, attended by key figures such as Heidi Overton, the CEO of Novo Nordisk, Maziar Mike Doustdar, the CEO of Eli Lilly, and U.S. Secretary of Commerce Howard Lutnick. The agreement is seen as a pivotal moment, especially as the country navigates a landscape marked by ongoing discussions around drug pricing.
As the industry gears up for the annual JPMorgan Healthcare Conference next week, executives, investors, and analysts are eagerly anticipating insights that the event will provide into the future of healthcare in 2026. Historically recognized as a major event for biotech and pharma stakeholders, this gathering is anticipated to set the tone for industry sentiment, with executives expected to share updates on business strategies, drug pipelines, and significant mergers and acquisitions.
The mood heading into 2026 contrasts with earlier expectations from 2025. Many industry leaders are relieved following landmark drug pricing agreements and the delay or cancellation of proposed tariffs on the pharmaceutical sector by the Trump administration. With pricing pressures less likely to dominate discussions, Wall Street’s attention may shift to another pressing issue: a looming patent cliff projected to impact the industry by around $300 billion by the end of the decade.
Major drugs facing a loss of exclusivity include Bristol Myers Squibb’s blood thinner, Eliquis, and Merck’s renowned cancer treatment, Keytruda. As these patents expire, drugmakers are under immense pressure to develop new products to mitigate revenue losses. Notably, Bristol Myers Squibb is expected to provide clarity this year regarding its growth potential post-2028, particularly in relation to its Cobenfy medication, recently approved for adults with schizophrenia.
In the race to manage patent expirations effectively, Merck has demonstrated that the potential impact of Keytruda’s loss of exclusivity may be manageable, especially in light of a newly approved, more convenient subcutaneous formulation of the drug that could safeguard a significant portion of its U.S. sales.
The conference will also shine a spotlight on obesity management, as companies like Novo Nordisk and Eli Lilly unveil their progress with GLP-1 treatments, including oral options. Novo Nordisk has recently started distributing its Wegovy pill, while Eli Lilly is anticipated to shed light on its upcoming GLP-1 medication, orforglipron, expected to receive FDA approval soon. Dynamics in the GLP-1 market are evolving, particularly with discussions surrounding direct-to-consumer sales and expanding Medicare coverage for obesity treatments anticipated to begin mid-year.
Other pharmaceutical players, including Amgen, AstraZeneca, and Pfizer—with its recent acquisition of obesity-focused biotech Metsera—are also expected to face inquiries about their strategies within the burgeoning weight loss market.
As the conference approaches, industry stakeholders await valuable updates and insights that could shape the healthcare landscape for the coming year. Attendees are encouraged to engage, share tips, or discuss new ideas, fostering collaboration and innovation within this vital sector.
